Results 91 to 100 of about 12,575 (207)

Post-Marketing Pharmacovigilance Study of Darunavir in the United Kingdom: An Analysis of Adverse Drug Reactions Reported to the MHRA

Pharmacoepidemiology
Background/Objectives: Human immunodeficiency virus (HIV) continues to be a global public health concern. Several antiretroviral drugs have been approved for the treatment, post-exposure, and pre-exposure prophylaxis of HIV. Darunavir (DRV) is a protease
Pono Pono, Vicky Cheng, Victoria Skerrett, Alan M. Jones   +3 more
doaj   +1 more source

A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).

PLoS ONE, 2019
BackgroundVery few data are available on treatment in HIV Late presenter population that still represents a clinical challenge.MethodsProspective, multicenter, randomized open-label, 2 arm, phase-3 trial comparing the 48-week virological response of two ...
Cristina Mussini, Enrica Roncaglia, Vanni Borghi, Stefano Rusconi, Silvia Nozza, Anna Maria Cattelan, Daniela Segala, Paolo Bonfanti, Antonio Di Biagio, Enrico Barchi, Emanuele Focà, Anna Degli Antoni, Stefano Bonora, Daniela Francisci, Silvia Limonta, Andrea Antinori, Gabriella D'Ettorre, Franco Maggiolo   +17 more
doaj   +1 more source

Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients [PDF]

, 2017
[Objectives] To evaluate if there are significant drug–drug interactions between cobicistat-boosted elvitegravir and 800 mg darunavir once daily taken simultaneously, as has been suggested previously.[Methods] The study population consisted of three ...
Lopez-Cortes, Luis F, Benmarzouk-Hidalgo, Omar J, Fernández-Magdaleno, Tamara, BenMarzouk-Hidalgo, O. J., Llaves, Silvia, Espinosa, Nuria, Viciana, Pompeyo, López-Cortés, Luis F., Gutierrez-Valencia, Alicia, Gutiérrez Valencia, Alicia   +9 more
core   +1 more source

Results of a comparative study of the efficacy of once daily darunavir/atazanavir in treatment-naïve patients with HIV infection

Терапевтический архив, 2014
AIM. To evaluate the efficacy of boosted darunavir and atazanavir used in antiretroviral therapy (ARVT) regimens for treatment-naïve HIV-infected patients with low baseline immune parameters and a high viral load. MATERIALS AND METHODS. The investigators
G F Moshkovich, S V Minaeva
doaj  

Chemical and Toxicological Analysis of Antiretroviral Drugs

Разработка и регистрация лекарственных средств, 2019
Introduction. Human Immunodeficiency Virus (HIV) is one of the main socially significant infection all over the world. HIV-positive patients take medical care, including antiretroviral drugs (ARVs) pharmacotherapy.
T. N. Komarov, M. V. Belova, D. D. Stolyarova, I. E. Shohin, D. S. Bogdanova, O. A. Miskiv, Yu. V. Medvedev, I. M. Korenskaya   +7 more
doaj   +1 more source

Pharmacokinetics of darunavir/ritonavir in Asian HIV-1-infected children aged >/=7 years [PDF]

, 2012
Item does not contain fulltextBACKGROUND: The Asian population, in general, has higher antiretroviral concentrations than those who are not Asian, but there are limited pharmacokinetic data for darunavir/ritonavir in Asian children.
Kerr, S.J., Tulathip Suwanlerk, Phongsamart, W., Nirun Vanprapar, Ananworanich, J., Burger, D.M., Jiratchiya Sophonphan, Prasitsuebsai, W., Chokephaibulkit, K., Sekar, V., Wittawatmongkol, O., Gorowara, M., Vanprapar, N., Wanatpreeya Phongsamart, Stephen J Kerr, Sophonphan, J., Thanyawee Puthanakit, Chayapa Pasomsap, Pasomsap, C., David Burger, Suwanlerk, T., Orasri Wittawatmongkol, Puthanakit, T., Kulkanya Chokephaibulkit, Wasana Prasitsuebsai, Jintanat Ananworanich, Meena Gorowara, Vanitha Sekar   +27 more
core   +1 more source

Reversibility of Neuropsychiatric Adverse Events after Switching to Darunavir/Cobicistat or Doravirine in Men on INSTI-Based Regimen

Viruses
Integrase strand transfer inhibitors (INSTI) are associated with neuropsychiatric adverse events (NPAEs). The aim of this study was to evaluate improvements in NPAEs after switching an INSTI-based regimen to darunavir/cobicistat (DRV/c) or doravirine ...
José Antonio Mata-Marín, Carina Aurora Juárez-Contreras, Mara Soraya Rodríguez-Evaristo, Olivia Concepción Martínez-Carrizales, Ericka Pompa-Mera, Alberto Chaparro Sánchez, Salma Triana-González, Ana Luz Cano-Díaz, Jesús Enrique Gaytán-Martínez   +8 more
doaj   +1 more source

Site dependent intestinal absorption of darunavir and its interaction with ketoconazole [PDF]

, 2013
The expression of P-gp increases from proximal to distal parts of the small intestine, whereas for P450 enzymes the expression is reported to be highest in duodenum and jejunum, decreasing to more distal sites.
Annaert, Pieter, Stappaerts, Jef, Augustijns, Patrick   +2 more
core   +1 more source

Influence of Darunavir: β-cyclodextrin complex on the solubility of Darunavir [PDF]

, 2014
Darunavir, a protease inhibitor used in the treatment of HIV infection, was complexed with β-cyclodextrin because of its low solubility in water and poor bioavailability, with the objective of improving the solubility of darunavir aiming subsequently the
Salgado, Hérida Regina Nunes, Corrêa, Josilene Chaves Ruela, Kogawa, Ana Carolina   +2 more
core   +2 more sources

Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1

ClinicoEconomics and Outcomes Research, 2023
Prina Donga,1 Bruno Emond,2 Carmine Rossi,2 Brahim K Bookhart,1 Johnnie Lee,1 Gabrielle Caron-Lapointe,2 Fangzhou Wei,3 Marie-Hélène Lafeuille2 1Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2Analysis Group, Inc, Montréal, QC, Canada; 3Analysis ...
Donga P, Emond B, Rossi C, Bookhart BK, Lee J, Caron-Lapointe G, Wei F, Lafeuille MH   +7 more
doaj